SNES — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-13

• •the size of the market for our products, and our ability to serve that market;

• •our belief that ContraPest® or Evolve® are novel in the pest control industry;

• •the success of competing products that are or become available;

• •existing regulations and regulatory developments towards first and second generation anti-coagulant rodenticides in the United States and other jurisdictions;

• •our belief that Evolve qualifies for exemption from registration as a minimum risk pesticide under Section 25(b) of the United States Environmental Protection Agency’s (the “EPA’s”) Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”);

Text removed vs the prior filing · source: 10-Q · 2025-11-10

• •our expectation that we will continue to incur significant expenses and operating losses for the foreseeable future;

• •our belief that if we encounter continued issues or delays in the commercialization of fertility control products, our expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the fu…

• •our expectation that if we are unable to generate additional funds in the future through additional financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations;

• •our expectation that significant operating losses will continue for the near future;

• •our ability to successfully commercialize our fertility control products and obtain and maintain regulatory approval for our products and product candidates;